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Pharmacological, genetic and expression studies implicate N-methyl-D-aspartate (NMDA) receptor hypofunction in
schizophrenia (SCZ). Similarly, several lines of evidence suggest that autism spectrum disorders (ASD) could be due to an
imbalance between excitatory and inhibitory neurotransmission. As part of a project aimed at exploring rare and/or de novo
mutations in neurodevelopmental disorders, we have sequenced the seven genes encoding for NMDA receptor subunits
(NMDARs)inalargecohortofindividualsaffectedwithSCZorASD(n¼429and428,respectively),parentsofthesesubjectsand
controls (n¼568). Here, weidentiﬁedtwo denovo mutations inpatients with sporadic SCZ inGRIN2A and one denovo mutation
in GRIN2B in a patient with ASD. Truncating mutations in GRIN2C, GRIN3A and GRIN3B were identiﬁed in both subjects and
controls, but no truncating mutations were found in the GRIN1, GRIN2A, GRIN2B and GRIN2D genes, both in patients and
controls, suggesting that these subunits are critical for neurodevelopment. The present results support the hypothesis that rare
de novo mutations in GRIN2A or GRIN2B can be associated with cases of sporadic SCZ or ASD, just as it has recently been
described for the related neurodevelopmental disease intellectual disability. The inﬂuence of genetic variants appears different,
depending on NMDAR subunits. Functional compensation could occur to counteract the loss of one allele in GRIN2C and GRIN3
family genes, whereas GRIN1, GRIN2A, GRIN2B and GRIN2D appear instrumental to normal brain development and function.
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Introduction
Glutamate is the major excitatory neurotransmitter of the
central nervous system and is implicated in many basic
neuronal functions and central nervous system processes, in
particular,learning,memoryandsynapticplasticity.N-methyl-
D-aspartate receptors (NMDAR) are voltage-dependant
ionotropic glutamate receptors and are tetramers containing
two NR1 subunits in association with two NR2 (A, B, C or D)
and/or NR3 (A or B) subunits. Many of the physiological and
pharmacological properties of the NMDAR depend on the
speciﬁc NR2 and NR3 subunits composition.
1 Behavioral
tasks that involve NMDAR include associative learning,
working memory, behavioral ﬂexibility or attention. Thus,
NMDAR signaling could be a point of convergence to explain
characteristic patterns of symptoms and neurocognitive
deﬁcits observed in neurodevelopmental disorders.
In schizophrenia (SCZ), dysregulation of brain glutamate
transmission through NMDAR has been proposed as an
etiological factor. Indeed, NMDAR antagonists (e.g., keta-
mine, phencyclidine) producebehavioral andcognitive deﬁcits
innormalsubjectsthatcloselymimicSCZ,
2–4andpatientswith
anti-NR1 encephalitis display many SCZ-like symptoms and/
or loss of memory.
5–7 Mutant mice lacking NR1 subunit in
about half of cortical interneurons early in post-natal develop-
ment exhibit anxiety-like behaviors and working memory
deﬁcits, emerging at adolescence.
8 In addition, NMDAR
density and NMDAR subunit composition are reported
abnormal in post-mortem brains of patients with SCZ.
9–15
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www.nature.com/tpSCZhasbeenassociatedwithgeneticvariantsinsomeofthe
NMDAR subunit(NMDARs) genesincluding GRIN2A,GRIN2B
and GRIN1, although contradictory results were reported (see
the SCZgene database: http://www.szgene.org/).
16 In addition,
several genes that have been associated with increased risk
for SCZ, including NRG1-erb4, serine racemase, DAO, G72
or dysbindin-1, are implicated in the modulation of NMDAR
activity.
17–19Lastly,theonlyconsistentreportfromindependant
genome-wide association studies in SCZ is the association
with genetic markers in the major histocompatibility complex
region,
20–22 and recent evidence suggests that major histo-
compatibility complex region is implicated in neuronal plasti-
city
23 and glutamatergic receptor modulation.
24
Dysfunction of NMDA signaling has also been implicated
in a wide range of neurological or neurodevelopmental
disorders such as intellectual disability (ID),
25,26 in which it
appears that speciﬁc NMDARs may have different roles
in synaptic plasticity and excitotoxicity.
27 In autism spec-
trum disorders (ASD), potentially causative mutations in
NMDARs genes have been recently reported,
28,29 and a
number of ASD animal models were associated with NMDA
abnormalities.
30–33 Moreover, disruption in the balance
between excitation and inhibition is a commonly proposed
disease mechanism for ASD,
34 and an open-label study
with memantine, an antagonist of the NMDAR, signiﬁcantly
improvedsymptoms.
35 Altogether,theliteraturesuggeststhat
NMDAR number and composition have a crucial role in
neurodevelopment and cognition.
Recent studies indicate that rare and penetrant de novo
mutations could account for some cases of SCZ. For
examples,rarechromosomalabnormalitiesaremorefrequent
in SCZ than in controls, especially rare de novo copy number
variations
22,36,37 similar to what had been reported in other
neurodevelopmental disorders such as ASD
38 and ID.
8,39
In addition, recent reports, including ours, issued from the
Synapse to Disease Project, support the implication of
de novo single nucleotide mutations in ID,
25,40–42
ASD
29,41,43 or SCZ.
44–47 Interestingly, among rare de novo
variants reported associated with SCZ, two affect genes that
may be linked to the glutamatergic synapses: SHANK3,
encoding a scaffolding protein at the excitatory synapse and
KIF17 encoding a synaptic motor protein, involved in the
transport of NMDA receptor 2B (NR2B) to the synapse.
48
As part of the Synapse to Disease Project, in which we
screened 600 synaptic genes, we screened all exons of the
seven NMDARs in 571 individuals, including 429 patients with
SCZ and 142 patients with ASD. We also screened all exons
of the NMDARs (except for GRIN3B and GRIN1)i n2 8 3
healthy controls. Further, we screened additional cohort of
ASD patients (n¼286) for GRIN2B, GRIN2C and GRIN3B,
and additional cohort of controls from the general population
(n¼285) for GRIN2C and GRIN3A.F o rGRIN1,w es c r e e n e d
only this general population cohort of controls. Finally, we
determinedtransmissionofalluniquevariants,identiﬁedinonly
one individual, by sequencing parents of the carrier (292 SCZ
and 404 ASD patients, with 2 parents available for screening).
We here report the identiﬁcation of de novo mutations in
patients with SCZ in the GRIN2A gene and in a patient with
ASD in the GRIN2B gene. Also, we report the absence of
truncating mutation in the GRIN1, GRIN2A, GRIN2B and
GRIN2D genes in patients or controls, whereas we identiﬁed
truncating mutations in the GRIN2C, GRIN3A and GRIN3B
genes in patients and controls.
Methods
Subject collection
SCZ cohort. Subjects with SCZ were selected from over 1000
families ascertained for genetic studies, for which DNA
samples were available. The screened cohort included 429
subjects with SCZ. We selected in priority patients with no
family history of psychiatric disorders (n¼188 patient) and
patients for which both parents were available (n¼292
patients with both parents). To ensure accurate diagnoses,
all individuals were evaluated by experienced investigators
(JR, LD, MOK and RJ) using the Diagnostic Interview for
Genetic Studies or the Kiddie Schedule for Affective Disorders
and SCZ and multidimensional neurological, psychological,
psychiatric and pharmacological assessments in the
recruiting centers. Family history for psychiatric disorders
was also collected using the Family Interview for Genetic
Studies. All Diagnostic Interview for Genetic Studies and
Family Interview for Genetic Studies have been reviewed by
two or more psychiatrists for a ﬁnal consensus diagnosis,
based on Diagnostic and Statistical Manual of Mentals
Disorders (DSM)-IIIR or DSM-IV at each center. For all
probands, speciﬁc inclusion criteria for the present study were
as follows: (1) the selected proband was deﬁnitely affected
with SCZ only, not schizophreniform psychosis or bipolar
disorders with psychosis; (2) in families with multiple affected
individuals, we selected the most severe SCZ case with early
(o18years) or childhood onset (o12years), and/or additional
neurodevelopmental problems, such as ID, dyslexia and
epilepsy, but not autistic disorder; for the childhood onset SCZ
cohort, ID and epilepsy were exclusionary; (3) Family history
was well documented. Finally, exclusion criteria included
patients with psychotic symptoms mainly caused by alcohol,
drug abuse, or other clinical diagnoses including cytogenetic
abnormalities. The ﬁnal panel of the samples of 429 SCZ
subjects were recruited from different centers, that is, 1) 28
cases with childhood-onset SCZ and 66 with later onset SCZ
from Judith L Rapoport (NIMH, Bethesda, MD, USA). Cases
with childhood onset SCZ were recruited in USA nationwide
and assessed as previously described.
49 Individuals in this
cohort known to carry the Velo-Cardio-Facial Syndrome
(VCFS) deletion on chromosome 22q11 were excluded; 2)
38 cases from Marie-Odile Krebs (Paris, France);
50 3) 84
cases from Lynn E De Lisi;
51 4) 7 cases of adult onset SCZ
selected from each of seven large highly consanguineous
pedigrees with X10 affected individuals with SCZ and
schizoaffective disorders from Pakistan; 5)144 cases from
Ridha Joober (Montreal, QC, Canada) including 39 cases
from Tunisia;
52 and 6) 62 cases from Hungary.
53 The detailed
description of recruitment and ascertainment strategy, diag-
nostic instruments and criteria have been reported by each
center in their previous publications.
ASD cohort. The ﬁnal panel of samples included 428 autistic
patients (404 with parental DNA of both parents available).
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described in detail elsewhere.
54 We screened 142 autistic
patients for the seven NMDAR genes, and 286 additional
cases were screened for variants in GRIN2B, GRIN2C and
GRIN3B. Brieﬂy, all subjects were diagnosed using DSM-IV
or DSM-IIIR criteria, and depending of the recruitment
site, Autism Diagnostic Interview-Revised and the Autism
Diagnostic Observation Schedule were used. In addition, the
Autism Screening Questionnaire was also completed for
all subjects. We excluded patients with an estimated mental
age o18 months, a diagnosis of Rett syndrome or childhood
disintegrative disorder, and patients with evidence of any
psychiatric and neurological conditions including birth anoxia,
rubella during pregnancy, fragile-X disorder, encephalitis,
phenylketonuria, tuberous sclerosis, Tourette and West
syndromes.
Control cohorts. Blood samples were obtained from a total of
568 control subjects. The ﬁrst control series comprised
healthy volunteers that were screened and selected using
standardized procedures. Only individuals without any
neuropsychiatric symptoms or family history of neuro-
psychiatric problems were included as SCZ-negative
controls. These included 283 adult subjects (131 males;
152 females), 225 of whom were of European origin and 58
were non-Europeans (Tunisian). The second group of
controls comprised 285 subjects from a general population
control group of mainly French Canadian origin, for whom we
also had parental DNA (Quebec Newborn Twin Study; 150
males, 135 females).
55 We have systematically sequenced
all exons of the seven NMDAR genes (except for GRIN3B
and GRIN1) in the cohort of healthy volunteer controls.
When rare truncating mutations were identiﬁed, we further
screened all exons in additional controls from general
population (Quebec Newborn Twin Study). For GRIN1,w e
screened only this general population cohort of controls.
DNA preparation. Genomic DNA was extracted from blood
using Puregene extraction kit (Gentra System, Minneapolis,
MN, USA). For certain individuals in whom blood DNA was
limiting, we used DNA isolated from a lymphoblastoid cell line
derived from the individual for the screen. In all cases, rare
mutations were conﬁrmed using blood-derived DNA to rule
out variations having arisen during production or growth of
the lymphoblastoid cell line.
Paternity testing. Paternity, maternity and unique genetic
identiﬁcation of each individual of all families (subject families
and controls) was conﬁrmed using 5–14 highly informative
unlinked microsatellite markers as described in Gauthier
et al.
46
Gene screening, variation analysis and bioinformatics. In
each proband, we sequenced the coding region and the
splice junction of GRIN1 (chr9: 140,033,609–140,063,207,
hg19 assembly), GRIN2A (chr16: 9,847,267–10,276,263),
GRIN2B (chr12: 13,714,410–14,133,022), GRIN2C (chr17:
72,838,168–72,856,007), GRIN2D (chr19: 48,898,132–
48,948,187), GRIN3A (chr9: 104,331,635–104,500,862).
GRIN3B (chr19: 1,000,437–1,009,723) was sequenced only
in patients. The detailed descriptions of the samples screened
for each NMDAR gene are mentioned in Table 1. Primers
were designed using the ExonPrimer program (Helmholtz
Center Munich, Munich, Germany) from the UCSC genome
browser (Supplementary Table 3). PCR products were
sequenced at the McGill University and Genome Quebec
Innovation Centre in Montreal, QC, Canada (http://
gqinnovationcenter.com) on a 3730XL DNA Analyzer
System (Applied Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA). In each case, variations were conﬁrmed
by re-amplifying the fragment and resequencing of the samples
from the proband and available parents, using reverse
and forward primers. PolyPhred (version 6.11), PolySCAN
(v.3.0) and Mutation Surveyor (version 3.10; Soft Genetics,
State College, PA, USA) were used for mutation detec-
tion analysis. The PolyPhen (http://genetics.bwh.harvard.edu/
pph), SIFT (http://blocks.fhcrc.org/sift/SIFT.html), Panther
(www.pantherdb.org/tools/csnpScoreForm.jsp) and SNAP
(http://www.rostlab.org/services/SNAP/) programs were used
to predict the overall severity of the missense mutations. In all
instances, default parameters were used for each program.
Results
We found three de novo mutations in patients with sporadic
ASD or SCZ in GRIN2A and GRIN2B (Table 2). We also
identiﬁed one truncating mutationsin GRIN2C,four truncating
mutations in GRIN3A and recurrent truncating mutations in
GRIN3B, both in patients and controls (Table 3). By contrast,
we found no truncating mutations in patients or in controls in
the GRIN1, GRIN2A, GRIN2B and GRIN2D genes. All three
Table 1 Genes and samples screened
Samples
SCZ ASD Controls QNTS Controls
GRIN1 429 subjects (292 trios) 142 trios 285 trios Not analyzed
GRIN2A 429 subjects (292 trios) 142 trios Not analyzed 283 subjects
GRIN2B 429 subjects (292 trios) 428 subjects (404 trios) Not analyzed 283 subjects
GRIN2C 429 subjects (292 trios) 428 subjects (404 trios) 285 trios 283 subjects
GRIN2D 429 subjects (292 trios) 142 trios Not analyzed 283 subjects
GRIN3A 429 subjects (292 trios) 142 trios 285 trios 283 subjects
GRIN3B 429 subjects (292 trios) 428 subjects (404 trios) Not analyzed Not analyzed
Abbreviations: ASD, autism spectrum disorders; SCZ, schizophrenia; QNTS, Quebec Newborn Twin Study.
Number of trios indicates individuals having parental DNA from both parents available.
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GRIN3were reported neither in the most recent 1000 genome
release nor in hapmap.
TwodenovomutationswereidentiﬁedintheGRIN2Agene.
The ﬁrst in a patient with SCZ with no familial history of SCZ
was a missense (c.2902G4A; p.A968T) located in the
intracellular domain of the protein. It was not predicted as
having important functional consequence based on in silico
analysis (SIFT, PolyPhen and SNAP; Table 2); nevertheless,
itmodiﬁedanaminoacidthatishighlyconservedinmammals.
The second one was a silent mutation, c.3669C4T identiﬁed
inanotherpatientwithsporadicSCZ, andwasnot predictedto
be damaging by in silico analysis. Paternal age was 39 and
maternal age was 29 for this patient. These mutations were
not found in the remaining 1707 chromosomes that had been
sequenced. None of these patients had a mental retardation
with 11 and 12 years of education, respectively.
A missense mutation (c.2473T4G; p.L825V) wasidentiﬁed
in the GRIN2B gene in a patient with ASD that had no family
history of neuropsychiatric disorders or ID. The mutation was
conﬁrmed by resequencing blood DNA of this patient and his
parents.Paternalagewas36andmaternalagewas32forthis
patient. This mutation was absent in the remaining 2279
chromosomes and was predicted by in silico analysis as
relatively damaging, as it occurred in the last transmembrane
domain that is highly conserved among species.
We further analyzed the prevalence of truncating mutations
in our subjects. We did not identify any truncating mutations in
the GRIN1, GRIN2A, GRIN2B and GRIN2D genes in 854
individualsincluding 429patientswith SCZ,142withASD and
283 healthy controls (285 controls from general population
for GRIN1). By contrast, we identiﬁed the same truncating
nonsense mutation in the GRIN2C gene (c.54G4A; p.W18X)
in two individuals. This mutation was ﬁrst identiﬁed in an ASD
patient, and this variant was transmitted from his normal
father, whereas there was history of mild learning disabilities
inthemother.Wealsofoundthismutationinacontrolfromthe
general population.
We also identiﬁed four truncating mutations in the GRIN3A
gene.Twoofthemwereindelscreatingframeshiftintheopen-
reading frame and creating nonsense codon, one in an
individual from the population control cohort (c.2349delC;
p.P783PfsX23) and one in a healthy control (c.2424_2425de-
lAA; p.Q808QfsX5). The two other truncating mutations were
single-nucleotide variants. The ﬁrst one (c.1522C4T;
p.Q508X) was identiﬁed in a patient diagnosed with catatonic
SCZ and was inherited from the mother who had clinical
characteristics ranging in the SCZ spectrum. The second
one (c.679G4T; p.E227X) was observed in a young control
from the general population. Finally, we observed frequent
(10%) truncating mutations in the GRIN3B gene in the
same proportion as described elsewhere in the general
population.
56
Overall, we identiﬁed 260 exonic variants in the seven
sequenced NMDARs genes, including 159 variants that were
not referenced in the dbSNP database (Build 132; Supple-
mentary Tables 1 and 2). These variants were all conﬁrmed
manually by genotyping the proband and in the respective
proband’s parents, when available, to determine their
inheritance. To avoid rare variants that could be linked to
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Translational Psychiatryethnic origin, we removed variants coming from patients with
non-Caucasian ethnicity. When doing so, we did not observe
either accumulation of rare variants in patients compared with
controls or accumulation of more damaging variants in
patients, based on in silico analysis.
Discussion
Here, we provide the ﬁrst systematic study of sequence
alterations in all NMDARs genes in ASD and SCZ, and report
several potentially damaging and/or de novo mutations.
Indeed, we identiﬁed potentially damaging de novo mutation
in GRIN2A and GRIN2B associated with sporadic cases of
SCZ and ASD, respectively, and truncating mutations in
GRIN2C, GRIN3A and GRIN3B, whereas neither truncating
nor de novo mutations were found in GRIN1 and GRIN2D.
Deep sequencing technologies have brought new insight in
the genetics of neurodevelopmental disorders including SCZ.
Recent reports of the literature have shown that there should
be, in average, less than two de novo mutations in the coding
sequence per individual and less than one de novo that would
have an effect on amino acid sequence per individual.
44,57,58
We here report on three de novo mutations, two in GRIN2A
in two patients suffering from SCZ, and one in GRIN2B in a
patient with autism. The mutation in GRIN2B is one of the
mutations quoted in a previous paper reporting an overall rate
of de novo mutation in autism or SCZ.
44 In this former paper
that considers the overall rate of de novo mutation, based on
partialresults,themutationwasunfortunatelymisclassiﬁedas
being in a patient with SCZ, whereas it is deﬁnitely in a patient
withASD.Thesemutationswerenotinheritedfromunaffected
parents, and the patients with de novo mutation in GRIN2A or
GRIN2B did not have a predisposing or causative mutation in
600 other synaptic genes that have been sequenced,
including SCZ-risk genes, such as DISC1 (data not shown).
Hence,itcouldbehypothesizedthatthesemutationscouldbe
associated with the pathogenesis of ASD or SCZ. This is
further supported by the observation that the missense
mutation in GRIN2B is predicted by in silico analysis to be
relatively damaging and it occurred in the last trans-
membrane domain that is highly conserved among species.
In addition, one of the de novo mutations identiﬁed in the
GRIN2A gene, is located in a domain that is highly conserved
in mammals and vertebrates, and is known to be the target of
post-translational modiﬁcations, especially phosphorylation.
In particular, it has been recently proposed that abnormalities
in the neuregulin 1-ErbB4 pathway, which has been impli-
cated in SCZ and known to contribute to NMDAR hypofunc-
tion, acts through NMDARs phosphorylation by the Src
tyrosine kinase.
18,19
Several studies have already screened for mutations in
some NMDARs genes in neurodevelopmental diseases.
Williams et al.
59 screened for mutations in the GRIN1 and
GRIN2 genes in patients with SCZ, but did not identify any
variants that were clearly relevant to the phenotype, with only
a single missense variant identiﬁed among 368 individuals
(including 184 controls). Endele et al.
25 screened for muta-
tions and cytogenetic abnormalities in the GRIN2A and
GRIN2B genes in patients with ID and found rare damaging
de novo mutations and truncating mutations in these genes,
indicating that these mutations can be pathogenic. Recently
Hamdan et al.
26 screened GRIN1 in patients with non-
syndromic ID and identiﬁed a de novo missense and one
amino acid in-frame insertion that altered the receptor’s
activity, the control population in this latter paper being the
same as the one used in the present report. Lastly, an exome
sequencing study published this year, identiﬁed several
potentially causative de novo mutations on patients with
ASD, one of them being in GRIN2B, within a splice site.
29 As
we do not provide direct evidence of a functional effect of
these mutations, we cannot deﬁnitely conclude on the causal
effect of de novo mutations identiﬁed in GRIN2A and GRIN2B
genes. It should however be emphasized that there were
no truncating mutations in at least 854 individuals (includ-
ing 283 healthy volunteers) in GRIN1, GRIN2A, GRIN2B
and GRIN2D, supporting the hypothesis of a high selection
pressure on these genes.
In addition to de novo mutations, we identiﬁed truncating
mutations in the GRIN2C, GRIN3A and GRIN3B genes in
patients, population controls and/or healthy volunteers. The
rate of mutations in the GRIN3B gene was in the same
proportion asdescribed in the general population, with around
10% of the individuals homozygous for truncating mutation.
56
As this relatively high rate of mutation and as GRIN3B is
mainly expressed in motor neurons, and thus a role in mental
disorders as SCZ and ASD is unlikely, the gene was not
further explored in controls.
56,60
The presence of truncating mutations in controls suggests
that loss of function of these subunits leads to little or no
effect. For the GRIN2C subunit, we identiﬁed the same
truncating mutation in a patient with autism and in a control.
Although the global functioning and learning abilities of this
Table 3 Details of rare truncating mutations in NMDAR subunits
Gene Sequence change Samples
Variant
type
Protein change Chr Chr Position
a Exon cDNA change ASD
frequency
SCZ
frequency
Controls
frequency
GRIN2C Nonsense p.W18X 17 72851178 1 c.54G4A 1/428 0/429 1/568
GRIN3A Nonsense p.E227X 9 104499583 1 c.679G4T 0/142 0/429 1/568
Nonsense p.Q508X 9 104433172 3 c.1522C4T 0/142 1/429 0/568
Indel p.P783PfsX23 9 104432345 3 c.2349delC 0/142 0/429 1/568
Indel p.Q808QfsX6 9 104390612_104390613 4 c.2424_2425delAA 0/142 0/429 1/568
Abbreviations: ASD, autism spectrum disorders; chr, chromosome; NMDAR, N-methyl-D-aspartate receptor subunit; SCZ, schizophrenia.
aPositions according to genome build 37.
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age at the time of his evaluation precludes from reaching ﬁrm
conclusions on the effect of this truncating mutation on his
future development.
On the other hand, the loss of function in one allele from
the GRIN3 family genes do not appear to have dramatic
consequences as truncating mutations were identiﬁed in
healthy controls, suggesting some functional compensations.
NMDAR containing GRIN2 subunits show large differences in
their pharmacological and electophysiological properties,
including glutamate afﬁnity, modulation by glycine, sensitivity
to Mg
2þ and channel kinetics. As they also show a distinct
spatial and chronological pattern of expression, it has
been suggested that these receptors may have unique roles
in brain development.
1 Unlike most NMDAR that contain
GRIN2subunits,whichtypicallyrequireglycineandglutamate
for activation, NMDAR that contain both GRIN1 and GRIN3
subunits are activated by glycine alone. When co-expressed
with GRIN1 and GRIN2 subunits, GRIN3 subunits can act
as negative modulators, reducing single-channel conduc-
tance and Ca
2þ permeability.
61 Thus, it is not surprising that
rare damaging mutations could have differential effects in the
GRIN2 and GRIN3 family of NMDARs.
We identiﬁed a large number of rare variants that are not
in the dbSNP databases. Based on in silico analysis, these
variants do not appear to be pathogenic on their own. Further,
most of them are inherited from unaffected parents and
someof them could belinked to the ethnic origin, asthey were
more frequent in the Tunisian samples. When excluding
the mutations found in subjects that were not of European
Caucasian origin, we did not observe any accumulation of
rare or more damaging variants in patients compared with
controls. Nevertheless, we cannot exclude complex gene
interaction that could occur with variants in other genes.
In conclusion, our data support the hypothesis that rare
de novo mutations in GRIN2A or GRIN2B could account for
some cases of sporadic SCZ or autism. They also further
support the implication of NMDARs in psychiatric disorders
with neurodevelopmental origin. Nevertheless, a distinct
pattern is observed between the different NMDARs. Truncat-
ing mutations in GRIN2C and GRIN3 were found in patients
and controls, whereas no truncating mutations were found in
GRIN1, GRIN2A, GRIN2B and GRIN2D. This could indicate
that GRIN1, GRIN2A, GRIN2B and GRIN2D families are
crucial in normal brain development and function and/or that
functional compensation could occur to counteract the loss of
one allele in GRIN2C and GRIN3 family genes.
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